Jamunarani Veeraraghavan

2.2k total citations
36 papers, 880 citations indexed

About

Jamunarani Veeraraghavan is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jamunarani Veeraraghavan has authored 36 papers receiving a total of 880 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 20 papers in Molecular Biology and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jamunarani Veeraraghavan's work include HER2/EGFR in Cancer Research (18 papers), Advanced Breast Cancer Therapies (10 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). Jamunarani Veeraraghavan is often cited by papers focused on HER2/EGFR in Cancer Research (18 papers), Advanced Breast Cancer Therapies (10 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). Jamunarani Veeraraghavan collaborates with scholars based in United States, Spain and Italy. Jamunarani Veeraraghavan's co-authors include Rachel Schiff, Natarajan Aravindan, Terence S. Herman, Mohan Natarajan, Mothaffar F. Rimawi, C. Kent Osborne, Carmine De Angelis, Vidyalakshmi Sethunath, Sheeja Aravindan and Xiao-Song Wang and has published in prestigious journals such as Journal of Biological Chemistry, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Jamunarani Veeraraghavan

36 papers receiving 870 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jamunarani Veeraraghavan United States 17 393 346 258 192 165 36 880
Subbulakshmi Virudachalam United States 18 705 1.8× 381 1.1× 274 1.1× 160 0.8× 148 0.9× 21 1.2k
Katja Wosikowski United States 17 459 1.2× 415 1.2× 142 0.6× 113 0.6× 84 0.5× 30 954
Bonnie Andrais Canada 17 633 1.6× 374 1.1× 259 1.0× 119 0.6× 114 0.7× 21 997
Abhijit Bhat United States 15 721 1.8× 331 1.0× 198 0.8× 80 0.4× 234 1.4× 28 1.2k
Sven Petersen Singapore 14 330 0.8× 454 1.3× 167 0.6× 318 1.7× 125 0.8× 21 1.3k
Jing‐Wen Bai China 17 572 1.5× 308 0.9× 269 1.0× 159 0.8× 64 0.4× 39 1.0k
Rhoda Arzoomanian United States 15 510 1.3× 319 0.9× 160 0.6× 148 0.8× 54 0.3× 27 947
Eugeni López‐Bonet Spain 20 743 1.9× 533 1.5× 339 1.3× 98 0.5× 92 0.6× 37 1.2k
Yu-Mei Feng China 21 847 2.2× 466 1.3× 383 1.5× 146 0.8× 47 0.3× 41 1.3k
Xiao-Feng Le United States 21 910 2.3× 462 1.3× 274 1.1× 92 0.5× 155 0.9× 23 1.3k

Countries citing papers authored by Jamunarani Veeraraghavan

Since Specialization
Citations

This map shows the geographic impact of Jamunarani Veeraraghavan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jamunarani Veeraraghavan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jamunarani Veeraraghavan more than expected).

Fields of papers citing papers by Jamunarani Veeraraghavan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jamunarani Veeraraghavan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jamunarani Veeraraghavan. The network helps show where Jamunarani Veeraraghavan may publish in the future.

Co-authorship network of co-authors of Jamunarani Veeraraghavan

This figure shows the co-authorship network connecting the top 25 collaborators of Jamunarani Veeraraghavan. A scholar is included among the top collaborators of Jamunarani Veeraraghavan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jamunarani Veeraraghavan. Jamunarani Veeraraghavan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Veeraraghavan, Jamunarani, Carmine De Angelis, Carolina Gutiérrez, et al.. (2025). HER2-Positive Breast Cancer Treatment and Resistance. Advances in experimental medicine and biology. 1464. 495–525. 3 indexed citations
2.
Bhat, Raksha R., Suhas Vasaikar, Sarmistha Nanda, et al.. (2025). Interactions between ADGRF1 (GPR110) and extracellular matrix proteins govern its effects on tumorigenesis in HER2‐positive breast cancer. British Journal of Pharmacology. 182(11). 2524–2541. 2 indexed citations
3.
Wang, Xian, Jamunarani Veeraraghavan, Lanfang Qin, et al.. (2021). Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer. Clinical Cancer Research. 27(9). 2648–2662. 8 indexed citations
4.
Veeraraghavan, Jamunarani, Ying Tan, Jinah Kim, et al.. (2020). A Novel Neoplastic Fusion Transcript, RAD51AP1-DYRK4 , Confers Sensitivity to the MEK Inhibitor Trametinib in Aggressive Breast Cancers. Clinical Cancer Research. 27(3). 785–798. 11 indexed citations
5.
Li, Li, Ling Lin, Jamunarani Veeraraghavan, et al.. (2020). Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance. Breast Cancer Research. 22(1). 84–84. 22 indexed citations
6.
Veeraraghavan, Jamunarani, Sarmistha Nanda, Vidyalakshmi Sethunath, et al.. (2020). Abstract 1911: HER2 L755S mutation is associated with acquired resistance to lapatinib and neratinib, and confers cross-resistance to tucatinib in HER2-positive breast cancer models. Cancer Research. 80(16_Supplement). 1911–1911. 10 indexed citations
7.
Rimawi, Mothaffar F., Polly Niravath, Tao Wang, et al.. (2019). TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer. Clinical Cancer Research. 26(4). 821–827. 34 indexed citations
8.
Veeraraghavan, Jamunarani, Vidyalakshmi Sethunath, Carmine De Angelis, et al.. (2019). Towards personalized treatment for early stage HER2-positive breast cancer. Nature Reviews Clinical Oncology. 17(4). 233–250. 183 indexed citations
9.
Nardone, Agostina, Hazel M. Weir, Oona Delpuech, et al.. (2018). The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance. British Journal of Cancer. 120(3). 331–339. 43 indexed citations
10.
Veeraraghavan, Jamunarani, Carmine De Angelis, Jorge S. Reis‐Filho, et al.. (2017). De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance. The Breast. 34. S19–S26. 41 indexed citations
11.
Kim, Jinah, Meenakshi Anurag, Jamunarani Veeraraghavan, et al.. (2016). Amplification of TLK2 Induces Genomic Instability via Impairing the G2–M Checkpoint. Molecular Cancer Research. 14(10). 920–927. 22 indexed citations
12.
Veeraraghavan, Jamunarani, Jiacheng Ma, Yiheng Hu, & Xiao-Song Wang. (2016). Recurrent and pathological gene fusions in breast cancer: current advances in genomic discovery and clinical implications. Breast Cancer Research and Treatment. 158(2). 219–232. 33 indexed citations
13.
Kim, Jinah, Ying Tan, Xian Wang, et al.. (2016). Comprehensive functional analysis of the tousled-like kinase 2 frequently amplified in aggressive luminal breast cancers. Nature Communications. 7(1). 12991–12991. 45 indexed citations
14.
Veeraraghavan, Jamunarani, Mohan Natarajan, Sheeja Aravindan, Terence S. Herman, & Natarajan Aravindan. (2011). Radiation-triggered Tumor Necrosis Factor (TNF) α-NFκB Cross-signaling Favors Survival Advantage in Human Neuroblastoma Cells. Journal of Biological Chemistry. 286(24). 21588–21600. 61 indexed citations
15.
Veeraraghavan, Jamunarani, Mohan Natarajan, Pallavi Lagisetty, et al.. (2011). Impact of Curcumin, Raspberry Extract, and Neem Leaf Extract on Rel Protein-Regulated Cell Death/Radiosensitization in Pancreatic Cancer Cells. Pancreas. 40(7). 1107–1119. 47 indexed citations
16.
Aravindan, Natarajan, Jamunarani Veeraraghavan, Rakhesh Madhusoodhanan, Terence S. Herman, & Mohan Natarajan. (2011). Curcumin Regulates Low-Linear Energy Transfer γ-Radiation-Induced NFκB-Dependent Telomerase Activity in Human Neuroblastoma Cells. International Journal of Radiation Oncology*Biology*Physics. 79(4). 1206–1215. 37 indexed citations
17.
18.
Veeraraghavan, Jamunarani, Mohan Natarajan, Terence S. Herman, & Natarajan Aravindan. (2010). Low-dose γ-radiation-induced oxidative stress response in mouse brain and gut: Regulation by NFκB–MnSOD cross-signaling. Mutation Research/Genetic Toxicology and Environmental Mutagenesis. 718(1-2). 44–55. 37 indexed citations
19.
Madhusoodhanan, Rakhesh, Mohan Natarajan, Jamunarani Veeraraghavan, et al.. (2009). NFκB Signaling Related Molecular Alterations in Human Neuroblastoma Cells after Fractionated Irradiation. Journal of Radiation Research. 50(4). 311–324. 18 indexed citations
20.
Madhusoodhanan, Rakhesh, et al.. (2009). NFκB activity and transcriptional responses in human breast adenocarcinoma cells after single and fractionated irradiation. Cancer Biology & Therapy. 8(9). 765–773. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Subbulakshmi Virudachalam Breakdown of academic impact, for papers by Katja Wosikowski Breakdown of academic impact, for papers by Bonnie Andrais Breakdown of academic impact, for papers by Abhijit Bhat Breakdown of academic impact, for papers by Sven Petersen Breakdown of academic impact, for papers by Jing‐Wen Bai Breakdown of academic impact, for papers by Rhoda Arzoomanian Breakdown of academic impact, for papers by Eugeni López‐Bonet Breakdown of academic impact, for papers by Yu-Mei Feng Breakdown of academic impact, for papers by Xiao-Feng Le
Rankless by CCL
2026